<DOC>
	<DOCNO>NCT02105155</DOCNO>
	<brief_summary>The best period conversion Prograf ( tacrolimus administer twice daily ) Advagraf ( once-daily prolonged-release tacrolimus ) remain unknown . The aim prospective , randomize , multicenter trial prove non-inferiority early conversion ( D7 ) versus conversion D90 liver transplantation . The primary objective evaluate incidence first biopsy-proven acute rejection 6 first month , prove non-inferiority conversion D7 + / - 3 versus conversion D90 + / - 5 ( reference group ) . If non-inferiority prove , two strategy compare term superiority . 250 patient include . Three ancillary study add : PK study subgroup 40 patient ( 20 patient per arm ) , assay calcineurin activity subgroup 40 patient , medicoeconomic study patient</brief_summary>
	<brief_title>Conversion Prograf® Advagraf® D7 Versus D90 After Liver Transplantation</brief_title>
	<detailed_description>Rationale : Conversion Prograf ( tacrolimus administer twice daily ) Advagraf ( once-daily prolonged-release tacrolimus ) currently propose stable de novo liver transplant recipient . However , early conversion ( around D7 transplantation ) , hospitalization , may difficult due frequent need dose adjustment Advagraf Prograf , consensus best period conversion . The aim prospective , randomize , multicenter trial prove non-inferiority - term efficacy - early conversion ( D7 ) versus conversion D90 liver transplantation . Primary objective : To evaluate incidence biopsy-proven acute rejection 6 first month liver transplantation , prove non-inferiority conversion D7 + / - 3 versus conversion D90 + / - 5 ( reference group ) . Secondary objective : Compare two strategy term : - Severity acute rejection ( criteres Banff 97 ) - Steroid-resistant acute rejection - Number dose adjustment obtain target trough level conversion - Patient graft survival Analyse PK profile two subgroup ( 20 patient arm ) Advagraf Measure calcineurin activity two group ( patient select PK analysis ) Evaluate tolerance , particular focus renal function 6 month ( glomerular filtration rate use MDRD4 ) adverse event . Primary endpoint : Percentage patient first episode biopsy-proven acute rejection . Methodology : Multicenter ( 13 French liver transplant center ) , randomize ( central randomisation ) , open study , non-inferiority , compare efficacy 6 month two strategy conversion Prograf Advagraf ( D7 + / - 3 versus D90 + / - 5 ) , addition mycophenolate mofetil steroid , liver transplant recipient . If non-inferiority prove , two strategy compare term superiority . Inclusion 250 patient ( analyse least 112 patient arm ) . Calculation sample size base follow data : Incidence acute rejection 6 month = 20 % 2 group , Non-inferiority margin = 15 % , alpha risk = 2.5 % , power = 80 % ) . Treatments : - Prograf introduce 0,1 - 0,2 mg/kg/day - Mycophenolate mofetil : 1g TD - Steroids accord current use center Trough blood concentration tacrolimus 8 - 15 ng/mL first 3 month , 5 à 12 ng/mL thereafter . PK study : For 40 patient include PK study ( 20 patient per arm ) , PK profile ( C0 , Cmax AUC ) establish 9 point : 0 ( Advagraf administration ) 20min , 40 min , 60 min , 2h , 3h , 4h , 6h , 8h . - 7 day conversion first group ( early conversion ) - 14 + / - 5 day conversion group ( conversion D90 ) Calcineurin activity assay blood sample use trough concentration determination D5 , D7 , M1 , M3 M6 baseline sample . Medicoeconomic study : The cost induce liver transplantation calculate patient include randomize accord French recommendation .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Inclusion Criteria : 18 75 year First liver transplantation No contraindication tacrolimus , mycophenolate mofetil steroid Informed consent sign French Health Assurance Exclusion Criteria : Combined transplantation Severe uncontrolled infection Hypersensitivity tacrolimus excipients , macrolides , mycophenolate mofetil excipients Pregnant lactate woman , woman childbearing potential without adequate method contraception Cancer pasthistory cancer basal squamous cell carcinoma hepatocellular carcinoma suitable liver transplantation Patients renal impairment GFR le 30ml/min HIV positivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Liver transplantation ,</keyword>
	<keyword>Conversion ( Prograf® Advagraf® ) ,</keyword>
	<keyword>Prograf® ,</keyword>
	<keyword>Advagraf® ,</keyword>
	<keyword>acute rejection ,</keyword>
	<keyword>GFR</keyword>
</DOC>